Vaccine Sales Market Report 2026-2036: 6.3% CAGR

Visiongain’s latest report, Vaccine Sales Market Report 2026-2036, provides detailed forecasts and strategic analysis across indication, type, route of administration, age group, and distribution channel segments, including technology trends, trade and supply chain dynamics, and competitive positioning.

The global vaccine sales market is valued at US$76.40 billion in 2026 and is projected to reach US$141.40 billion by 2036, at a CAGR of 6.3% during the forecast period. Growth is driven by rising infectious disease prevalence, expanding government-funded immunisation programmes across low- and middle-income countries, and accelerating investment in next-generation vaccine platforms including mRNA, viral vector, and needle-free delivery technologies.

Key Market Insights

The global vaccine sales market will reach US$141.40 billion by 2036, growing at a CAGR of 6.3%
Growth is driven by infectious disease resurgence, expanding LMIC immunisation programmes, and next-generation platform innovation
Key regions: North America, Europe, Asia Pacific
Leading companies: GSK, Pfizer, Sanofi, Moderna, Serum Institute of India
Key trend: Transition toward mRNA and needle-free vaccine platforms supporting pandemic preparedness and oncology applications

Market Drivers

Rising Prevalence of Infectious Disease

The rising prevalence of infectious diseases continues to strengthen global vaccine demand and reinforce the importance of sustained immunisation programmes. In East Asia and the Pacific, measles cases have increased sharply, with Vietnam reporting more than 80,000 suspected cases in 2025 alongside rising incidence in Mongolia, Cambodia, and the Philippines. Globally, measles cases reached approximately 10.3 million in 2025, reflecting a nearly 20% year-on-year increase across more than 130 countries.

The resurgence extends to whooping cough and other vaccine-preventable infections, reflecting declining routine immunisation coverage in several regions. In April 2026, Bangladesh launched an emergency measles vaccination campaign targeting over one million children in response to a fast-spreading outbreak, reinforcing the role of large-scale vaccine deployment in addressing rising infectious disease burden.

Government-Funded National Immunisation Programmes in LMICs

Government-funded immunisation programmes in low- and middle-income countries remain a major driver of vaccine sales by translating public health priorities into recurring procurement demand. WHO data for 2024 showed that global DTP3 coverage reached 85% and HPV first-dose coverage increased to 31%, reflecting continued programme expansion and new vaccine introductions. In February 2026, the Government of India launched a nationwide HPV vaccination programme for girls aged 14 years, targeting approximately 11.5 million beneficiaries annually across all states and union territories, representing a major expansion in vaccine access and procurement volume.

In October 2025, Ghana launched its first nationwide HPV vaccination campaign targeting approximately 2.4 million girls aged 9 to 14 years, implemented through school-based and community outreach delivery over a five-day period, with plans for integration into routine immunisation schedules.

Technology & Innovation

Advancements in Vaccine Platform Technologies

Platform-based technologies including mRNA, viral vector, and DNA approaches are expanding vaccine pipelines and supporting development beyond traditional infectious diseases. Candidates such as mRNA-4157 demonstrate the growing application of mRNA technology in oncology, while ongoing work in HIV, Nipah virus, and pandemic influenza reflects continued diversification of the vaccine development landscape.

Innovation in formulation and delivery is also supporting wider adoption. Intranasal vaccines and oral delivery formats simplify administration and improve patient acceptance, particularly among paediatric populations. In December 2025, CEPI committed up to US$54.3 million to support a Phase 3 trial of Moderna’s mRNA-based H5 pandemic influenza vaccine candidate (mRNA-1018), advancing the first mRNA influenza vaccine into pivotal-stage development and strengthening the commercial pipeline for next-generation vaccine platforms.

Trade & Supply Chain Dynamics

U.S. tariffs on pharmaceutical inputs, biologics manufacturing equipment, and cold-chain materials are increasing cost pressures across the global vaccine sales market. Vaccine supply chains rely on cross-border sourcing of ingredients, vials, stoppers, packaging, and manufacturing technologies, creating exposure to import-related cost escalation that affects both producer margins and public procurement budgets.

The impact is uneven across the market. Larger manufacturers with U.S.-based facilities are better positioned to adapt, while smaller and import-dependent suppliers face greater margin pressure. Over the forecast period, tariff dynamics are expected to accelerate localisation of vaccine manufacturing, regional fill-finish capacity, and supplier diversification, contributing to a more geographically distributed and cost-resilient market structure.

Commercial Impact

Cost pressure: Rising input and compliance costs are affecting procurement economics for government-funded programmes, particularly for low-margin paediatric vaccines and large-volume public health initiatives
Supply chain shifts: Companies are accelerating localisation of manufacturing, regional fill-finish expansion, and supplier diversification to reduce tariff exposure and improve supply resilience
Margin implications: Import-dependent suppliers and smaller developers face greater cost pressure and reduced competitiveness relative to manufacturers with diversified regional footprints
Competitive positioning: Manufacturers with regionally anchored supply networks and established government procurement relationships are better positioned to manage cost volatility

Market Opportunities

Growing Focus on Next-Generation Vaccines

The vaccine market is increasingly shifting toward next-generation platforms that offer broader protection, improved efficacy, and greater delivery convenience. mRNA-based vaccines, needle-free delivery systems, and broadly protective influenza vaccines are gaining importance as healthcare systems seek to improve immunisation coverage and respond to evolving pathogen dynamics.

In February 2026, the European Commission committed €225 million to support development and pre-commercial procurement of next-generation influenza vaccines, selecting SK bioscience, IDT Biologika, and Vaxxas to develop needle-free patch-based influenza vaccines targeting seasonal and pandemic markets. In August 2025, Moderna received FDA approval for updated COVID-19 vaccines targeting the LP.8.1 variant, enabling continued commercial deployment of variant-adapted mRNA vaccines in seasonal immunisation programmes.

R&D Investment Accelerating Pipeline Development

R&D investment is increasingly influencing the vaccine sales market by accelerating development of pipeline candidates and supporting clearer commercialisation pathways. Gavi’s Vaccine Investment Strategy has prioritised emerging and underutilised vaccines including tuberculosis, dengue, and group B streptococcus, encouraging alignment between R&D activity and funded immunisation demand. In September 2025, Evaxion Biotech out-licensed its infectious disease vaccine candidate EVX-B3 to Merck & Co., with an upfront payment of US$7.5 million and potential milestone and royalty payments of up to US$592 million, highlighting the role of R&D partnerships in enabling future vaccine sales growth.

Competitive Landscape

The major players operating in the vaccine sales market include AstraZeneca, Bavarian Nordic, Bharat Biotech, BioNTech SE, CSL, DAIICHI SANKYO, Emergent BioSolutions, GSK plc, INOVIO Pharmaceuticals, Merck & Co., Moderna, Novavax, Panacea Biotec, Pfizer, Sanofi, Serum Institute of India, SINOVAC, SINOPHARM, Takeda Pharmaceutical, Tanabe Pharma Corporation, and Valneva SE.

These companies are strengthening their market positions through M&A, R&D investment, strategic collaborations, regional manufacturing expansion, and new product launches, with increasing focus on next-generation platform development and government procurement partnerships.

Recent Developments

March 2026 – Emergent BioSolutions secured a contract valued at approximately US$54 million to deliver VIGIV to the U.S. Administration for Strategic Preparedness and Response for smallpox preparedness, under an existing 10-year contract with HHS
March 2026 – GSK received FDA approval to expand the Arexvy RSV vaccine indication to adults aged 18 to 49 years at increased risk for lower respiratory tract disease, extending the approved range from adults aged 50 and older
March 2026 – Bavarian Nordic and Serum Institute of India expanded their strategic partnership to include a full technology transfer of the chikungunya vaccine (CHIKV VLP) manufacturing process to SII, enabling future supply to endemic low- and middle-income countries
March 2026 – CSL Seqirus entered a long-term agreement with the PAHO Regional Revolving Fund to supply its influenza vaccine portfolio to Latin America, working with Sinergium Biotech to localise vaccine filling and distribution in the region

Frequently Asked Questions

What is driving growth in the vaccine sales market?
Growth is driven by rising infectious disease prevalence, expanding government-funded immunisation programmes in low- and middle-income countries, and accelerating investment in next-generation vaccine platforms including mRNA, viral vector, and needle-free delivery technologies.

How are trade and supply chain dynamics affecting the market?
U.S. tariffs on pharmaceutical inputs and biologics manufacturing equipment are increasing cost pressures across the market, affecting both producer margins and public procurement budgets. This is accelerating localisation of vaccine manufacturing and investment in regional fill-finish capacity across North America, Europe, and Asia Pacific.

Who are the leading companies in the market?
Key players include GSK, Pfizer, Sanofi, Moderna, Serum Institute of India, AstraZeneca, and Bavarian Nordic.

About Visiongain

Established in 1998, Visiongain is an independent publisher of analyst-led market intelligence, delivering data-driven research, forecasts, and strategic insight across global industries and emerging markets. Visiongain supports evidence-based decision-making for investment, procurement, and long-term strategic planning.